MedTrace Logo

JAK-inhibition in Recurrent Classical Hodgkin Lymphoma

NCT02164500 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2020-04-06

No results posted yet for this study

Summary

The Purpose of this trial is:

* to determine the overall response rate (ORR, complete response \[CR\] + partial response \[PR\]) in patients with relapsed or refractory HL
* to determine the safety profile of ruxolitinib in patients with relapsed or refractory HL

Conditions

  • Recurrent Classical Hodgkin Lymphoma

Interventions

DRUG

Ruxolitinib

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2019-05-17
Completion
2019-05-17

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02164500 on ClinicalTrials.gov